Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant is focused in the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Australia, Switzerland and Central Europe.
In February 2011, Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A., announced their agreement for Valeant to acquire PharmaSwiss, a privately-owned branded generics and over-the-counter (OTC) pharmaceutical company based in Zug, Switzerland. The acquisition was completed in March 2011. PharmaSwiss has a broad product portfolio in seven therapeutic areas and operations in nineteen countries throughout Central and Eastern Europe, including Greece and Israel.